^
BIOMARKER:
Chr del(17p)
Chr del(17p)
CLL
zanubrutinib
Sensitive
:
A2
EHA 2021 - 4d
Chr del(17p)
CLL
venetoclax
Sensitive
:
A1
EHA 2021 - 4d
Chr del(17p)
CLL
ibrutinib
Sensitive
:
A1
EHA 2021 - 4d
Chr del(17p)
Multiple Myeloma
Isa-KRd
Sensitive
:
C2
EHA 2021 - 4d
Chr del(17p)
Small Lymphocytic Lymphoma
LOXO-305
Sensitive
:
C3
EHA 2021 - 4d
Chr del(17p)
CLL
LOXO-305
Sensitive
:
C3
EHA 2021 - 4d
Chr del(17p)
CLL
FCR
Sensitive
:
C3
EHA 2021 - 4d
Chr del(17p)
Multiple Myeloma
thalidomide
Resistant
:
C3
EHA 2021 - 4d
Chr del(17p)
CLL
venetoclax + obinutuzumab
Sensitive
:
A1
Chr del(17p)
CLL
rituximab + idelalisib
Sensitive
:
A1
Chr del(17p)
CLL
acalabrutinib
Sensitive
:
A1
Chr del(17p)
CLL
idelalisib + ofatumumab
Sensitive
:
A1
Chr del(17p)
CLL
ofatumumab
Sensitive
:
A2
Chr del(17p)
CLL
rituximab
Sensitive
:
A2
Chr del(17p)
CLL
venetoclax + rituximab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
A2
Chr del(17p)
CLL
idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
ofatumumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
duvelisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + alemtuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive
:
A2
Chr del(17p)
CLL
lenalidomide
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our